Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00192296 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate the Safety, Tolerability,Immunogenicity, and Pharmacokinetics of MEDI-528 in Healthy Adult Volunteers
A Phase 1 study, sponsored by MedImmune.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT00192296 is a Phase 1 study that has completed, run by MedImmune. The registered enrollment target is 24 participants.
The verdict
NCT00192296, a Phase 1 study, has completed, sponsored by MedImmune.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
Phase I study to evaluate the safety and tolerability of escalating single IV doses of MEDI-528.
Interventions
- BIOLOGICAL MEDI-528 0.3 mg/kg
- BIOLOGICAL MEDI-528 1 mg/kg
- BIOLOGICAL MEDI-528 3 mg/kg
- BIOLOGICAL MEDI-528 9 mg/kg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2004-08 |
| Est. Completion | 2005-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00192296
The ClinicalTrials.gov registry entry for NCT00192296 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MedImmune, which has 210 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which MEDI-528 0.3 mg/kg is the first listed.
NCT00192296 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00192296 about?
NCT00192296 is a clinical study titled "Study to Evaluate the Safety, Tolerability,Immunogenicity, and Pharmacokinetics of MEDI-528 in Healthy Adult Volunteers". Phase I study to evaluate the safety and tolerability of escalating single IV doses of MEDI-528.
What is the current status of trial NCT00192296?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2004-08. Estimated completion is 2005-03.
What interventions are being tested in trial NCT00192296?
The interventions under investigation include: MEDI-528 0.3 mg/kg (BIOLOGICAL), MEDI-528 1 mg/kg (BIOLOGICAL), MEDI-528 3 mg/kg (BIOLOGICAL), MEDI-528 9 mg/kg (BIOLOGICAL).
Who is sponsoring clinical trial NCT00192296?
This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.